Methods of obtaining a specific binding member that binds eotaxin
View Patent ↗Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.
1. An isolated nucleic acid which comprises a nucleotide sequence encoding a specific binding member that binds human eotaxin, wherein said specific binding member comprises:
(i) an antibody VH domain comprising the VH CDR1 amino acid sequence provided in SEQ ID NO:5, the VH CDR2 amino acid sequence provided in SEQ ID NO:6, and the VH CDR3 amino acid sequence provided in SEQ ID NO:7; and
(ii) an antibody VL domain comprising the VL CDR1 amino acid sequence provided in SEQ ID NO:8, the VL CDR2 amino acid sequence provided in SEQ ID NO:9, and the VL CDR3 amino acid sequence provided in SEQ ID NO:10.
2. The isolated nucleic acid of claim 1 wherein the VH domain comprises the amino acid sequence provided in SEQ ID NO:2.
3. The isolated nucleic acid of claim 2 wherein the VL domain comprises the amino acid sequence provided in SEQ ID NO:4.
4. The isolated nucleic acid of claim 3 wherein the binding member neutralizes eotaxin.
5. The isolated nucleic acid of claim 3 wherein the binding member comprises an scFv antibody molecule.
6. The isolated nucleic acid of claim 3 wherein the specific binding member comprises an antibody constant region.
7. The isolated nucleic acid of claim 3 wherein the specific binding member comprises a whole antibody.
8. The isolated nucleic acid of claim 3 wherein the specific binding member comprises an IgG4 constant region.
9. A host cell transformed with the nucleic acid of claim 3 .
10. The isolated nucleic acid of claim 1 wherein the VL domain comprises the amino acid sequence provided in SEQ ID NO:4.
11. The isolated nucleic acid of claim 1 wherein the binding member neutralizes eotaxin.
12. The isolated nucleic acid of claim 1 wherein the binding member comprises an scFv antibody molecule.
13. The isolated nucleic acid of claim 1 wherein the specific binding member comprises an antibody constant region.
14. The isolated nucleic acid of claim 1 wherein the specific binding member comprises a whole antibody.
15. The isolated nucleic acid of claim 1 wherein the specific binding member comprises an IgG4 constant region.
16. A host cell transformed with the nucleic acid of claim 1 .
17. An isolated nucleic acid which comprises a nucleotide sequence encoding a specific binding member that binds human eotaxin, wherein said specific binding member comprises an antibody VL domain comprising the VL amino acid sequence provided in SEQ ID NO:4.
18. An isolated nucleic acid which comprises a nucleotide sequence encoding a specific binding member that binds human eotaxin, wherein said specific binding member comprises an antibody VH domain comprising the VH amino acid sequence provided in SEQ ID NO:2.